- Home
- / Cumulus Neuroscience
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cumulus Neuroscience financials data including stock price, CreditSafe score, balance sheet, and acquistions and subsidiaries.
Total Funding
$5.5 M
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|
| Cash | 6.8M | 4.3M | 2.2M |
| Accounts Receivable | 357.7K | 105.2K | 430.9K |
| Prepaid Expenses | 24.3K | 48.8K | 138.3K |
| Current Assets | 7.3M | 5.1M | 3.3M |
| PP&E | 19.7K | 36.5K | 57.1K |
| Total Assets | 7.3M | 5.1M | 3.3M |
| Accounts Payable | 75.8K | 236.1K | 126.8K |
| Current Liabilities | 590.9K | 485.4K | 8.1M |
| Non-Current Liabilities | 6.1M | 6.6M | |
| Total Liabilities | 6.7M | 7.1M | 8.1M |
| Common Stock | 85.0 | 88.0 | 90.0 |
| Additional Paid-in Capital | 376.4K | 376.4K | 376.4K |
| Retained Earnings | 217.4K | (2.4M) | (5.1M) |
| Total Equity | 593.9K | (2.0M) | (4.8M) |
| Financial Leverage | 12.3 | -2.6 | -0.7 |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |